Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Leuk Res. 2018 Sep:72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10.

¹ The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States. Electronic address: joshua_zeidner@med.unc.edu.
² University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States.
³ The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.
⁴ Mayo Clinic, Rochester, MN, United States.
⁵ The Blood and Marrow Transplant Program at Northside Hospital, Bone Marrow Transplant Group of Georgia, Atlanta, GA, United States.
⁶ Vanderbilt-Ingram Cancer Center, Nashvile, TN, United States.
⁷ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
⁸ Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, United States; University of Texas, MD Anderson Cancer Center, Houston, TX, United States.
⁹ Texas Oncology, Baylor Charles A. Simmons Cancer Center, Dallas, TX, United States.
¹⁰ Mayo Clinic, Scottsdale, AZ, United States; New York University School of Medicine, Laura & Isaac Perlmutter Cancer Center, New York, NY, United States.
¹¹ The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States; University of Maryland Medical Center, Stewart Greenebaum Cancer Center, Baltimore, MD, United States.
¹² National Cancer Institute, Rockville, MD, United States.

No abstract available

Publication types